/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has established a Sepsis & Inflammation Scientific Advisory Board to provide guidance on the development of new therapeutics, including a device to reduce the incidence of sepsis in combat-injured soldiers being advanced under a contract from the Defense Advanced Research Projects Agency (DARPA). The initial members of the Aethlon Sepsis & Inflammation Scientific Advisory Board are Irshad Chaudry, Ph.D., Charles J. Fisher, Jr., MD and Geert Schmid-Schonbein, Ph.D.
About Dr. Chaudry
Dr. Chaudry is the Editor-in-Chief of the journal SHOCK®, a
leading research publication that reviews novel therapeutic
advances to address shock, trauma, sepsis, inflammation,
ischemia, and related pathobiological states, with
particular emphasis on the biologic mechanisms that
determine the response to such injury. Dr. Chaudry
received a B.S. as well as a M.S. with honors from Sind
University, and a Ph.D. from Monash University, Australia.
After his postdoctoral training at Toronto University,
Canada, he was appointed Instructor and
subsequently an Assistant Professor at the Jewish
Hospital and Washington University School of Medicine. He
then moved to Yale University as an Associate Professor and
subsequently became a Professor. He moved to Michigan State
University in 1986 as Professor and Director of Research
and in 1996 became the Director of the Center for Surgical
Research at Brown University. In 2000, he became the
Director of the Center for Surgical Research at the
University of Alabama at Birmingham, and the Vice Chairman
of the Department of Surgery. He has over 500 publications
to his credit and is a recipient of the NIH MERIT award.
About Dr. Fisher
Dr. Fisher, founder & CEO of Margaux Biologics, Inc., is a
physician scientist with a distinguished career in both
academia and industry spanning over 30 years. Prior
to joining industry, Dr. Fisher served as Professor and
Head of Critical Care Medicine at The Cleveland Clinic
Foundation, and has held professor, division chief and
director positions at the University of California at Davis
Medical Center, Case Western Reserve University and The
Cleveland Clinic Foundation. His research in sepsis,
host defense and endothelial dysfunction led to his
assisting in the founding of Incyte, and his later
recruitment to Eli Lilly & Co, where he led the Xigris
(activated Protein C) Global Product Team and successfully
registered the first drug approved for the treatment of
sepsis. He was recruited to Abbott Laboratories as
Vice President for Global Pharmaceutical Development and,
among other accomplishments, led the registration of Humira
(first fully humanized anti-TNF mab). Other medical
firsts include his contributions to the development of, and
later approval of, sTNF:fc (Enbrel, 1st soluble anti-TNF
tx) and IL-1ra (Kinneret, 1st anti-IL-1 tx). Dr.
Fisher has numerous patents and publications to his
credit. Prior to founding Margaux Biologics, he was
Chief Medical Officer and Executive Vice President of
Cardiome Pharma Corp. where he led the team that invented,
developed, registered and sold to Merck ($800M)
vernakalant, a novel, first in class, multi-ion channel
drug for atrial fibrillation (Brinavess).
Additionally, Dr. Fisher is a decorated, multi tour combat veteran, with extensive military experience in special operations. He is a Life Member of the Special Operations Medical Association (SOMA), has served as a member of the Defense Science Research Council and on DARPA panels, including one focused on universal host defense. His unique background of direct patient care, basic and clinical research, on the ground combat experience, and leadership at all levels, has led to an exemplary track record of building teams, delivering results, medical firsts and saving lives.
About Dr. Schmid- Schonbein
Dr. Schmid-Schonbein is Distinguished Professor of
Bioengineering, Adjunct Professor in Medicine at the
University of California, San Diego (UCSD) and director of
the UCSD Microcirculation Laboratory where he and his team
are studying organ injury mechanisms, apoptosis in
hypertension, and triggers for inflammation in the blood
circulation. Dr. Schmid-Schonbein earned his Ph.D. in
bioengineering from UCSD in 1976. After a three-year
post-doctoral fellowship at Columbia University, he
returned to UCSD in 1979 as an assistant professor.
Some of Dr. Schmid-Schonbein's early research
discoveries involved the behavior of infection-fighting
white blood cells. Using engineering techniques, he made
the first determination of the force with which white blood
cells adhere to the walls of blood vessels as part of the
initial process of inflammation. Later, Dr.
Schmid-Schonbein concluded that the survival of an acutely
ill patient can hinge on the degree to which white blood
cells are activated. Recently his group discovered a
mechanism that leads to activation of white blood cells,
which is due to digestive enzymes and may cause
cardiovascular disease. Among his many distinctions, Dr.
Schmid-Schonbein is a member of the National Academy of
Engineering and a fellow of the American Heart Association.
He is a founding fellow of the American Institute for
Medical and Biological Engineering, and winner of the
Melville Medal from the American Society of Mechanical
Engineering.
About Aethlon Medical
The Aethlon Medical mission is to create innovative medical
devices that address unmet medical needs in cancer,
infectious disease, and other life-threatening conditions.
Our Aethlon ADAPT™ System is a revenue-stage technology
platform that provides the basis for a new class of
therapeutics that target the selective removal of disease
enabling particles from the entire circulatory system. The
Aethlon ADAPT™ product pipeline includes the Aethlon
Hemopurifier® to address infectious disease and cancer;
HER2osome™ to target HER2+ breast cancer, and a medical
device being developed under a contract with the Defense
Advanced Research Projects Agency (DARPA) that would reduce
the incidence of sepsis in combat-injured soldiers and
civilians. For more information, please visit .
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the ability for the Company to derive business partnerships or future revenue streams using the Aethlon ADAPT™ system including the ability to introduce a targeted breast cancer therapy known as HER2osome™, there is no assurance that FDA will approve the initiation of the company's clinical programs or provide market clearance of the company's products, the ability to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts:
James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications
858.459.7800 x307
jps@aethlonmedical.com
SOURCE Aethlon Medical, Inc.
distribué par | Ce noodl a été diffusé par Aethlon Medical Inc. et initialement mise en ligne sur le site http://www.aethlonmedical.com. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-12 14:25:56 PM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |